A retrospective analysis of cisplatin, pemetrexed, and bevacizumab in previously treated non-small-cell lung cancer

被引：5

作者：

Liu, Ke-Jun ^{[1
,2
]}

Wu, Hai-Ying ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China

[2] Dongguan Peoples Hosp, Dept Med Oncol, Dongguan, Peoples R China

来源：

ONCOTARGET | 2015年 / 6卷 / 26期

关键词：

non-small-cell lung cancer (NSCLC); bevacizumab; platinum-based chemotherapy; PHASE-III TRIAL; ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; PLUS CARBOPLATIN; 2ND-LINE THERAPY; RANDOMIZED-TRIAL; 1ST-LINE THERAPY; GEMCITABINE; COMBINATION; ERLOTINIB;

D O I：

10.18632/oncotarget.4262

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with non-small-cell lung cancer (NSCLC) often have an advanced disease when firstly diagnosed. Bevacizumab is a monoclonal antibody against vascular endothelial growth factor receptor (VEGFR). In this study, we retrospectively analyzed the efficacy of cisplatin, pemetrexed, and bevacizumab in previously treated advanced NSCLC. Results showed that the objective response rate(ORR) of this novel regimen is 43%, median progression-free survival (PFS) was 5.2 months (95% CI, 3.7 to 6.7 months) and median overall survival (OS) was 11.4 months (95% CI, 8.8 to 13.9 months). Adverse events were generally mild, ranging from grade 1 to grade 3. In conclusion, the combination of cisplatin, pemetrexed, and bevacizumab obtained promising results in selected patients with NSCLC. Randomized clinical trials are needed to further investigate the efficacy of this regimen.

引用

收藏

页码：22750 / 22757

页数：8

相关论文

共 40 条

[1] Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non-Small-Cell Lung Cancer: NCCTG and SWOG Study N0426 [J].

Adjei, Alex A. ;

Mandrekar, Sumithra J. ;

Dy, Grace K. ;

Molina, Julian R. ;

Adjei, Araba A. ;

Gandara, David R. ;

Ziegler, Katie L. Allen ;

Stella, Philip J. ;

Rowland, Kendrith M., Jr. ;

Schild, Steven E. ;

Zinner, Ralph G. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (04) :614-619

[2] Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (MO22089) [J].

Barlesi, Fabrice ;

Scherpereel, Arnaud ;

Rittmeyer, Achim ;

Pazzola, Antonio ;

Tur, Neus Ferrer ;

Kim, Joo-Hang ;

Ahn, Myung-Ju ;

Aerts, Joachim G. J. V. ;

Gorbunova, Vera ;

Vikstrom, Anders ;

Wong, Elaine K. ;

Perez-Moreno, Pablo ;

Mitchell, Lada ;

Groen, Harry J. M. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (24) :3004-+

[3] Tumorigenesis and the angiogenic switch [J].

Bergers, G ;

Benjamin, LE .

NATURE REVIEWS CANCER, 2003, 3 (06) :401-410

[4] Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood [J].

Bremnes, RM ;

Camps, C ;

Sirera, R .

LUNG CANCER, 2006, 51 (02) :143-158

[5] FDA drug approval summary:: Bevacizumab (Avastin®) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer [J].

Cohen, Martin H. ;

Gootenberg, Joe ;

Keegan, Patricia ;

Pazdur, Richard .

ONCOLOGIST, 2007, 12 (06) :713-718

[6] Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study [J].

Deng, Ting ;

Zhang, Le ;

Liu, Xiao-jian ;

Xu, Jian-ming ;

Bai, Yu-xian ;

Wang, Yan ;

Han, Yu ;

Li, Yu-hong ;

Ba, Yi .

MEDICAL ONCOLOGY, 2013, 30 (04)

[7] The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC) [J].

Ding, Lingyu ;

Liu, Kejun ;

Jiang, Zhelong ;

Chen, Qi ;

Zhou, Ningning ;

Liang, Ying ;

Gao, Hongfei ;

Hong, Xiangchan ;

Wu, Haiying .

TUMOR BIOLOGY, 2015, 36 (04) :2491-2499

[8] Role of vascular endothelial growth factor in Physiologic and Pathologic angiogenesis: Therapeutic implications [J].

Ferrara, N .

SEMINARS IN ONCOLOGY, 2002, 29 (06) :10-14

[9] The biology of VEGF and its receptors [J].

Ferrara, N ;

Gerber, HP ;

LeCouter, J .

NATURE MEDICINE, 2003, 9 (06) :669-676

[10] ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS [J].

FOLKMAN, J ;

MERLER, E ;

ABERNATHY, C ;

WILLIAMS, G .

JOURNAL OF EXPERIMENTAL MEDICINE, 1971, 133 (02) :275-+

← 1 2 3 4 →